Mr. Vic Neufeld reports

APHRIA ANNOUNCES CLOSING OF BOUGHT DEAL FINANCING

Aphria Inc. has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' overallotment option. A total of 12,689,675 common shares of the company were sold at a price of $7.25 per share, for aggregate gross proceeds of $92,000,144. The offering was underwritten by a syndicate of underwriters led by Clarus Securities Inc., and included Cormark Securities Inc., Canaccord Genuity Corp. and PI Financial Corp.

The net proceeds of the offering are expected to be used in connection with the company's construction or acquisition of domestic production facilities, if required to support provincialism within the Cannabis Act, construction or acquisition of domestic retail facilities for distribution of cannabis under the Cannabis Act, in those provinces which may allow it, strategic investments to enhance the company's product offerings or cultivation capabilities and non-United States international strategic investments, including direct investment or construction or acquisition of production facilities in new markets, located in non-United States federal legal markets, all related to cannabis production facilities.

Until spent by the company, the net proceeds of the offering will be held as cash balances in the company's bank account or invested at the discretion of the company's board of directors.

The shares were offered for sale in each of the provinces of Canada, other than the province of Quebec, by short form prospectus, and in those jurisdictions outside of Canada and the United States which were agreed to by the company and the underwriters, where the shares were issued on a private placement basis, exempt from any prospectus, registration or other similar requirements.

About Aphria Inc.

Aphria, one of Canada's lowest-cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ont., the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. The company is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

We seek Safe Harbor.